Dipatimenti Yapadziko Lonse

Pa Epulo 25, 2025, InnoCare Pharma idalengeza kuti mbadwo watsopano wa pan-TRK inhibitor zurletrectinib (ICP-723) wapatsidwa mwayi wowunikiranso ndi Center for Drug Evaluation (CDE) ya China National Medical Products Administration (NMPA), yomwe idavomereza New Drug Application (NDA) ya z...Werengani zambiri»

Pa Epulo 25, 2025, Innovent Biologics yalengeza kuti bungwe la National Medical Products Administration (NMPA) la ku China lavomereza New Drug Application (NDA) ya limertinib ngati chithandizo choyamba kwa odwala akuluakulu omwe ali ndi khansa ya m'mapapo yopanda maselo ang'onoang'ono (NSCLC) yomwe yakula kwambiri m'deralo...Werengani zambiri»

Pa Epulo 23, penpulimab ya Akeso idavomerezedwa ndi Food and Drug Administration ndi cisplatin kapena carboplatin ndi gemcitabine kuti igwiritsidwe ntchito pochiza akuluakulu omwe ali ndi khansa ya m'mphuno yobwerezabwereza kapena yofalikira ya nasopharyngeal carcinoma (NPC). FDA idavomerezanso penpulimab-kcqx ngati cholakwa...Werengani zambiri»

Pa 16 Marichi, 2025, Akeso adalengeza kuti antibody yake yatsopano yodzipangira yokha yotsutsana ndi PD-1 monoclonal, penpulimab, yavomerezedwa mwalamulo ndi National Medical Products Administration (NMPA) kuti igwiritsidwe ntchito pochiza khansa ya m'mphuno yobwerezabwereza kapena yofalikira (NPC) pamodzi ...Werengani zambiri»

Pa Epulo 24, 2025, GenFleet Therapeutics idalengeza kuti US Food and Drug Administration (FDA) yavomereza kugwiritsa ntchito mankhwala atsopano (IND) a GFH375/VS-7375, mankhwala oletsa kumwa a KRAS G12D (ON/OFF), kuti ayesedwe kuchipatala pochiza odwala omwe ali ndi chotupa champhamvu omwe ali ndi kusintha kwa KRAS G12D. Kafukufukuyu...Werengani zambiri»

Pa Epulo 17, 2025, Hansoh Pharmaceutical yalengeza kuti mankhwala opangidwa okha a B7-H3-target antibody-drug conjugate (ADC) HS-20093 a Gululi kuti agwiritsidwe ntchito jakisoni avomerezedwa kuti aphatikizidwe ngati mankhwala opangidwa ndi Breakthrough-Therapy ndi National Medical Products Administration (NMPA) ya China, ...Werengani zambiri»

Pa Epulo 15, 2025, InnoCare Pharma idalengeza kuti Center for Drug Evaluation (CDE) ya China National Medical Products Administration (NMPA) yavomereza New Drug Application (NDA) ya mbadwo watsopano wa pan-TRK inhibitor zurletrectinib (ICP-723) yochizira matenda a akuluakulu ndi achinyamata...Werengani zambiri»

Posachedwapa, GenFleet yalengeza za kafukufuku wa KROCUS, fulzerasib (GFH925, KRAS G12C inhibitor) pamodzi ndi cetuximab pochiza khansa ya m'mapapo yopanda maselo ang'onoang'ono (NSCLC), mu chidule chomwe chinaperekedwa pakamwa pa msonkhano wa 2025 European Lung Cancer Conf...Werengani zambiri»

PLB1004, yopangidwa ndi Beijing Avistone Biotechnology Co., Ltd., ndi mankhwala otetezeka, osankha bwino, komanso ogwira ntchito bwino otchedwa tyrosine kinase inhibitor (EGFR-TKI) omwe amagwiritsidwa ntchito pochiza khansa ya m'mapapo yopanda maselo ang'onoang'ono (NSCLC). Pa Epulo 9, 2025, National Medical Products Admi...Werengani zambiri»

Pa Marichi 13, 2025, magazini yapamwamba yapadziko lonse ya Nature Medicine inafalitsa mayeso a MediLink a B7-H3 okhudzana ndi mankhwala opha tizilombo toyambitsa matenda (ADC) YL201 Phase 1/1b. Mayesowa anaphatikizapo gawo lokulitsa mlingo (gawo 1) ndi gawo lokulitsa mlingo (gawo 1b). Odwala onse 312 analembetsa m'magawo onse...Werengani zambiri»

Pa 21 Marichi, 2025, Immunofoco idalengeza kuti chithandizo cha maselo a EpCAM chodziyimira pawokha, IMC001, chaperekedwa chilolezo ndi Center for Drug Evaluation (CDE) pansi pa National Medical Products Administration (NMPA) ku China chifukwa cha kafukufuku wake wachiwiri watsopano...Werengani zambiri»

Pa 31 Marichi, 2025, Innovent Biologics idalengeza kuti Center for Drug Evaluation (CDE) ya China's National Medical Products Administration (NMPA) yapereka Breakthrough Therapy Designation (BTD) ya IBI363, puloteni yoyamba ya PD-1/IL-2α-bias bispecific antibody fusion protein, ngati monotherapy ya ...Werengani zambiri»